Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 8 B, 2009, Pages 2673-2683

  Huynh, Hung ^a   Ngo, Van Chanh ^a   Koong, Heng Nung ^a   Poon, Donald ^a   Choo, Su Pin ^a   Thng, Choon Hua ^a   Chow, Pierce ^b   Ong, Hock Soo ^b   Chung, Alexander ^b   Soo, Khee Chee ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Angiogenesis; Hepatocellular carcinoma; MTOR; Vascular endothelial growth factor

Indexed keywords

ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PYRIDINE DERIVATIVE; RAPAMYCIN; SORAFENIB;

ANIMAL; ARTICLE; CELL DIVISION; DRUG EFFECT; LIVER TUMOR; MOUSE; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CELL DIVISION; CELL LINE, TUMOR; LIVER NEOPLASMS, EXPERIMENTAL; MICE; PHOSPHORYLATION; PYRIDINES; SIROLIMUS;

MAMMALIA;

EID: 67649715548     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00692.x     Document Type: Article

References (38)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005 55 : 10 30.
2. Smith RA, Cokkinides V, Eyre HJ. American Cancer Society Guidelines for the Early Detection of Cancer, 2005. CA Cancer J Clin. 2005 55 : 31 44.
3. Nagasue N, Kohno H, Chang YC, et al. Liver resection for hepatocellular carcinoma. Results of 229 consecutive patients during 11 years. Ann Surg. 1993 217 : 375 384. (Pubitemid 23115341)
4. Yamamoto J, Kosuge T, Takayama T, et al. Recurrence of hepatocellular carcinoma after surgery. Br J Surg. 1996 83 : 1219 1222.
5. Colombo M. Hepatocellular carcinoma. J Hepatol. 1992 15 : 225 236.
6. Lai EC, Fan ST, Lo CM, et al. Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Ann Surg. 1995 221 : 291 298.
7. Takenaka K, Kawahara N, Yamamoto K, et al. Results of 280 liver resections for hepatocellular carcinoma. Arch Surg. 1996 131 : 71 6.
8. Zhu AX. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be Oncologist. 2006 11 : 790 800.
9. Huynh HT, Nguyen TT, Chow PK, et al. Over-expression of MEK-MAPK in hepatocellular carcinoma: Its role in tumor progression and apoptosis. BMC Gastroenterol. 2003 3 : 19.
10. Karasarides M, Chiloeches A, Hayward R, et al. B-RAF is a therapeutic target in melanoma. Oncogene. 2004 23 : 6292 6298.
11. Tannapfel A, Sommerer F, Benicke M, et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut. 2003 52 : 706 712. (Pubitemid 36528874)
12. Hwang YH, Choi JY, Kim S, et al. Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma. Hepatol Res. 2004 29 : 113 121.
13. Schmitz KJ, Wohlschlaeger J, Lang H, et al. Activation of the ERK and AKT signaling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol. 2008 48 : 83 90.
14. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004 64 : 7099 7109.
15. Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006 66 : 11851 11858.
16. Carlomagno F, Anaganti S, Guida T, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst. 2006 98 : 326 334.
17. Llovet J, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008 359 : 378 390.
18. Huynh H, Soo KC, Chow PK, et al. Xenografts of human hepatocellular carcinoma: a useful model for testing drugs. Clin Cancer Res. 2006 12 : 4306 4314.
19. Boise LH, Gonzalez-Garcia M, Postema CE, et al. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell. 1993 74 : 597 608.
20. Hatai T, Matsuzawa A, Inoshita S, et al. Execution of apoptosis signal-regulating kinase 1 (ASK1)-induced apoptosis by the mitochondria- dependent caspase activation. J Biol Chem. 2000 275 : 26576 26581.
21. Ballif BA, Blenis J. Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth Differ. 2001 12 : 397 408.
22. Tran J, Rak J, Sheehan C, et al. Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem Biophys Res Commun. 1999 264 : 781 788.
23. Conway EM, Collen D, Carmeliet P. Molecular mechanisms of blood vessel growth. Cardiovasc Res. 2001 49 : 507 521.
24. Erber R, Thurnher A, Katsen AD, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 2004 18 : 338 340.
25. Becker G, Schmitt-Graeff A, Ertelt V, et al. CD117 (c-kit) expression in human hepatocellular carcinoma. Clin Oncol (R Coll Radiol). 2007 19 : 204 208.
26. Potti A, Ganti AK, Tendulkar K, et al. HER-2/neu and CD117 (C-kit) overexpression in hepatocellular and pancreatic carcinoma. Anticancer Res. 2003 23 : 2671 2674. (Pubitemid 36897142)
27. Went PT, Dirnhofer S, Bundi M, et al. Prevalence of KIT expression in human tumors. J Clin Oncol. 2004 22 : 4514 4522.
28. Eckel F, von Delius S, Mayr M, et al. Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma. Oncol. 2005 69 : 363 371.
29. Yu C, Bruzek LM, Meng XW, et al. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene. 2005 24 : 6861 6869.
30. Ichijo H, Nishida E, Irie K, et al. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science. 1997 275 : 90 4.
31. Chang HY, Nishitoh H, Yang X, et al. Activation of apoptosis signal-regulating kinase 1 (ASK1) by the adapter protein Daxx. Science. 1998 281 : 1860 1863.
32. Saitoh M, Nishitoh H, Fujii M, et al. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J. 1998 17 : 2596 2606.
33. Chen J, Fujii K, Zhang L, et al. Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism. Proc Natl Acad Sci USA. 2001 98 : 7783 7788.
34. Lee HS, Huang AM, Huang GT, et al. Hepatocyte growth factor stimulates the growth and activates mitogen-activated protein kinase in human hepatoma cells. J Biomed Sci. 1998 5 : 180 184.
35. Sahin F, Kannangai R, Adegbola O, et al. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res. 2004 10 : 8421 8425.
36. Lee JW, Soung YH, Kim SY, et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene. 2005 24 : 1477 1480.
37. Elsharkawi M, Staib L, Henne-Bruns D, et al. Complete remission of posttransplant lung metastases from hepatocellular carcinoma under therapy with sirolimus and mycophenolate mofetil. Transplantation. 2005 79 : 855 857.
38. Stippel DL, Kasper HU, Schleimer K, et al. Successful use of sirolimus in a patient with bulky ovarian metastasis of hepatocellular carcinoma after liver transplantation. Transplant Proc. 2005 37 : 2185 2187.